Skip to main content

Table 5 Patient benefits related to medications for AR taken during the past month at time of consultation

From: Severity and disease control before house dust mite immunotherapy initiation: ANTARES a French observational survey

 

Percentage of patients helped rather/a lota

p value**

AIT (N = 1012), %

No-AIT (N = 301), %

Total (N = 1313), %

To have a treatment which is easy to use

71.6

69.8 

71.2

0.541

To have confidence in the therapy

62.9

61.4

62.6

0.635

To be relieved of all symptoms

60.3

67.2

61.9

0.031

To not have sneezing impulses

58.3

62.2

59.2

0.230

To be able to breathe through my nose more freely

55.8

66.2

58.2

0.001

To no longer have a runny or blocked nose

56.5

63.0

58.0

0.049

To experience more enjoyment of life

58.3

53.9

57.3

0.188

To be able to engage in normal leisure activities

57.5

53.4

56.6

0.219

To not experience eye, nose or palate stinging anymore

53.5

56.6

54.2

0.361

To be able to stay outdoors without symptoms

52.8

56.5

53.6

0.264

To be able to sleep better

53.5

48.8

52.5

0.156

To reduce the frequency of visits to the physician

50.4

48.4

49.9

0.566

To be able to concentrate better at work

49.3

50.3

49.6

0.763

To have no fear that the disease will become worse

49.2

49.0

49.1

0.950

To be more productive in everyday life

49.1

46.5

48.5

0.447

To not have burning or watery eyes anymore

48.3

44.7

47.5

0.285

To have fewer side effects

46.9

42.7

45.9

0.207

To feel more comfortable in public

45.3

46.1

45.5

0.818

To feel less burdened in your relationship

44.2

45.9

44.6

0.622

To spend less time on daily treatment

42.8

45.9

43.5

0.357

To feel less tired or groggy

42.6

41.8

42.4

0.804

To have fewer out-of-pocket treatment expenses

42.6

35.5

41.0

0.036

To feel less irritated

40.0

36.2

39.1

0.252

To feel less depressed

35.4

34.3

35.1

0.741

To be able to have a normal sex life

32.8

35.3

33.4

0.503

  1. Analysis of the patient benefits questionnaires (PBQ) completed the day of the consultation correspond to the benefits that the patient expressed relative to the previous symptomatic therapeutic management for AR. Patient benefits are ordered by decreasing importance of the corresponding need. Treatment-related benefits are rated using a five-point scale from ‘did not help at all’ to ‘helped a lot’
  2. ** Chi squared test
  3. aPercentage of patients with benefits achieved by treatments for AR from ‘rather helped’ to ‘helped a lot’ at allergen immunotherapy initiation